ADVERTISEMENT
Conference Coverage
Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer
Jane Meisel, MD
06/03/2024
Jane Meisel, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.
Source:
Meisel J. Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY 2.2 trial. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA509
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement